Skip to content

IDEAYA Biosciences, Inc. IDYA Short- term Investments

Short- term Investments at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
Erasca, Inc. logo
Erasca, Inc.ERAS
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Roivant Sciences logo
Roivant SciencesROIV
Gilead Sciences logo
Gilead SciencesGILD
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s short- term investments?
IDEAYA Biosciences, Inc. (IDYA) reported short- term investments of $513.68M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s short- term investments changed year-over-year?
IDEAYA Biosciences, Inc.'s short- term investments decreased by 8.7% year-over-year, from $562.51M to $513.68M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s short- term investments?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s short- term investments has grown at a 20.0% compound annual growth rate (CAGR), from $211.55M to $526.56M.